EDITORIAL

“Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies

  • Zhiqiang An
Expand
  • The Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, U

Published date: 01 Mar 2018

Copyright

2017 The Author(s) 2017. This article is an open access publication

Cite this article

Zhiqiang An . “Magic Bullets” at the center stage of immune therapy: a special issue on therapeutic antibodies[J]. Protein & Cell, 2018 , 9(1) : 1 -2 . DOI: 10.1007/s13238-017-0488-1

1
An Z (2009) Therapeutic monoclonal antibodies: from bench to clinic. Hoboken, Wiley

2
An Z (2010) Monoclonal antibodies—a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319–330

3
Bardwell PD, Staron MM, Liu J, Tao Q, Scesney S, Bukofzer G, Rodriguez LE, Choi CH, Wang J, Chang Q, (2017) Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig. Protein Cell 9:121–129

4
Emmons C, Hunsicker LG (1987) Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med 77:78–82

5
Kang C, Xia L, Chen Y, Zhang T, Wang Y, Zhou B, You M, Yuan Q, Tzeng CM, An Z, (2017) A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys. Protein Cell 9:130–134

6
Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497

7
Liu L (2017) Pharmacokinetics of monoclonal antibodies and Fcfusion proteins. Protein Cell 9:15–32

8
Mimura Y, Katoh T, Saldova R, O’Flaherty R, Izumi T, Mimura-Kimura Y, Utsunomiya T, Mizukami Y, Yamamoto K, Matsumoto T, (2017) Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy. Protein Cell 9:47–62

9
Simeon R, Chen Z (2017) In vitro-engineered non-antibody protein therapeutics. Protein Cell 9:3–14

10
Strohl WR (2017) Current progress in innovative engineered antibodies. Protein Cell 9:86–120

11
Tan S, Liu K, Chai Y, Zhang CW, Gao S, Gao GF, Qi J (2017) Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell 9:135–139

12
Tsuchikama K, An Z (2016) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33–46

13
Wang X, An Z, Luo W, Xia N, Zhao Q (2017a) Molecular and functional analysis of monoclonal antibodies in support of biologics development. Protein Cell 9:74–85

14
Wang X, Mathieu M, Brezski RJ (2017b) IgG Fc engineering to modulate antibody effector functions. Protein Cell 9:63–73

Outlines

/